Stocktoria
TG THERAPEUTICS, INC. TGTX
TG THERAPEUTICS, INC. statistics & valuation
Market cap$8.5B
P / E19.1×
P / S13.9×
P / B13.2×
Net margin72.6%
Return on equity69.0%
FCF margin-4.1%
Net debt$166.5M
Net debt / EBITDA1.3×
Enterprise value USD$8.7B
EV / EBITDA70.6×
Earnings yield EBIT/EV1.4%
Return on capital13.6%
Graham number -68%$15.82
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($15.82); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 20.0% | 12.7% | 8.8% | -7839.0% | -5154.3% | -179996.1% | -111220.4% | -114736.8% | -78100.0% | -51953.3% |
| Net margin | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | — | — | — | — | — |
| FCF margin | -4.1% | -12.3% | -13.4% | -6326.2% | -4425.7% | -141357.9% | -87458.6% | -84878.3% | -61685.5% | -40744.1% |
| Return on assets | 42.1% | 4.0% | 3.8% | -115.6% | -91.7% | — | — | — | — | — |
| Return on equity | 69.0% | 10.5% | 7.9% | -382.0% | -146.8% | — | — | — | — | — |
| Debt / equity | 0.38× | 1.10× | 0.63× | 1.21× | 0.29× | 0.06× | 0.75× | 0.00× | — | — |
| Current ratio | 4.10 | 6.25 | 5.92 | 3.16 | 5.06 | 6.99 | 1.77 | 2.03 | 3.34 | 3.01 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.